| Literature DB >> 34924946 |
Alexandre A Lussier1,2,3, Tamara S Bodnar4, Joanne Weinberg4.
Abstract
Prenatal alcohol exposure can impact virtually all body systems, resulting in a host of structural, neurocognitive, and behavioral abnormalities. Among the adverse impacts associated with prenatal alcohol exposure are alterations in immune function, including an increased incidence of infections and alterations in immune/neuroimmune parameters that last throughout the life-course. Epigenetic patterns are also highly sensitive to prenatal alcohol exposure, with widespread alcohol-related alterations to epigenetic profiles, including changes in DNA methylation, histone modifications, and miRNA expression. Importantly, epigenetic programs are crucial for immune system development, impacting key processes such as immune cell fate, differentiation, and activation. In addition to their role in development, epigenetic mechanisms are emerging as attractive candidates for the biological embedding of environmental factors on immune function and as mediators between early-life exposures and long-term health. Here, following an overview of the impact of prenatal alcohol exposure on immune function and epigenetic patterns, we discuss the potential role for epigenetic mechanisms in reprogramming of immune function and the consequences for health and development. We highlight a range of both clinical and animal studies to provide insights into the array of immune genes impacted by alcohol-related epigenetic reprogramming. Finally, we discuss potential consequences of alcohol-related reprogramming of immune/neuroimmune functions and their effects on the increased susceptibility to mental health disorders. Overall, the collective findings from animal models and clinical studies highlight a compelling relationship between the immune system and epigenetic pathways. These findings have important implications for our understanding of the biological mechanisms underlying the long-term and multisystem effects of prenatal alcohol exposure, laying the groundwork for possible novel interventions and therapeutic strategies to treat individuals prenatally exposed to alcohol.Entities:
Keywords: Fetal Alcohol Spectrum Disorder (FASD); development; epigenetics; immune function; prenatal alcohol exposure (PAE)
Year: 2021 PMID: 34924946 PMCID: PMC8680672 DOI: 10.3389/fnins.2021.788630
Source DB: PubMed Journal: Front Neurosci ISSN: 1662-453X Impact factor: 4.677
FIGURE 1Summary figure. (1) Prenatal alcohol exposure (PAE) can result in (2) maternal immune system activation, altering the fine cytokine balance during pregnancy, which in turn impacts the developing immune system of the fetus. In turn, both direct effects of PAE and alcohol-induced maternal immune activation may result changes in (3) epigenetic mechanisms, which include alterations to DNA methylation levels, histone modification patterns, and miRNAs expression levels. These epigenetic changes are likely important mechanistic drivers of (4) life-long impairments in offspring immune function and (5) neuroimmune system alterations, including microglial activation and central cytokine changes. Together, offspring central and peripheral immune system activation, by way of epigenetic changes, are hypothesized as driving, at least in part, the increased risk of mental health conditions, such as depression and anxiety, in alcohol-exposed offspring. Created with BioRender.com.
Studies showing the impact of prenatal/early postnatal (third trimester equivalent) alcohol exposure on central cytokine levels.
|
|
|
|
|
|
|
|
|
|
|
| Mouse (C57BL/6) | Intra-esophageal gavage at 4 g/kg/day from P4-9 | P10 | Males, females (combined) | Hippocampus | IL-1β, TNF-α, CCL2 | ↑ | mRNA |
| Cerebellum | IL-1β, TNF-α, CCL2 | ↑ | ||||||
| Cortex | IL-1β, TNF-α | ↑ | ||||||
|
| Rat (Sprague Dawley) | Alcohol vapor (8.03 g/dL ± 21 at 4 h) from P3-5 | P4, 6 | Male | Cerebellar vermis | IL-1β | ↑ | mRNA |
| P4 | TNF-α | ↑ | ||||||
| P4 | Hippocampus | TNF-α | ↑ | |||||
|
| Rat (Sprague Dawley) | Liquid ethanol diet (6.37% v/v) from GD 1–21 | P8 | Female | Hippocampus | IL-1β, IL-2, TNF-α, IFN-γ, IL-4, IL-5 | ↑ | Protein |
| Prefrontal cortex | IL-6, IL-5 | ↑ | ||||||
| Hypothalamus | IL-1β, IL-2, TNF-α | ↓ | ||||||
|
| Rat (Long Evans) | Intragastric intubation (5.25 g/kg/day) from P4-9 | P10 | Male | Hippocampus | CCL4, TGF-β | ↑ | mRNA |
|
| Rat (Wistar) | Intragastric intubation (5 g/kg/day) from P7-9 | P28 | Male | Hippocampus | TNF-α, IL-1β, TGF-β | ↑ | Protein |
| Cortex | TNF-α, IL-1β, TGF-β | ↑ | ||||||
|
| Mouse (C57BL/6) | Intraperitoneal administration (0.03 mL/g) on GD8 | 6 h after ethanol treatment | Unknown | Whole embryo | IL-6, CXCL1, G-CSF IL-1β, IL-13 | ↑ ↓ | Protein |
|
| Mouse (C57BL/6) | Intraperitoneal administration (0.03 mL/g) on GD8 | E9.25 | Unknown | Brain | IL-1β, TNF-α | ↑ | Protein |
|
| Mouse (C57BL/6) | Water containing alcohol (20% v/v) from GD 1–21 | P70 | Male | Prefrontal cortex | IL-1β | ↑ | Protein |
|
| Rat (Sprague Dawley) | Intragastric intubation (2 g/kg twice per day) GD 10–16 | E17 | Female, male | Hippocampus/cortex | CCL3, CCL6, CCL9, CXCL9, CXCL11, IL-21, IL-5, TNF-β, Osm, TNF-α, TNFrsf10 | ↑ | mRNA |
| Male | CCL2, CCL5, CCL9, CXCL10, IL-5 | ↓ | ||||||
| Female | CCL2, CCL5, CCL9, CXCL10, IL-5 | ↑ |
GD, gestational day; E, embryonic day; P, postnatal day.
Studies involving a second hit/challenge were excluded.
Differential effects of PAE on the epigenetic profiles of immune genes.
|
|
|
|
|
| ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
| Mouse | Embryo | GD 10 | 400 mg/dL | 44 h | GD 8.25 | 279 | 7.9% | KLRC3, PSMC3 | FABP5, HMOX1, |
| FGFRL1, | MALT1, PDK1, PPP3CB | KLRC3, PPP3CB, PTPN11 | |
|
| Mouse | NS-5 neural stem cells (cultured) | NA | 400 mg/dL + FGF2 | 2 days | NA | 46 | 6.5% | JUN | DTL |
| JUN | ||||
| Mouse | NS-5 neural stem cells (cultured) | NA | 400 mg/dL + TGFB1 | 2 days | NA | 146 | 2.7% | BIRC5 |
| PAK1, PAK3 | PAK1 | |||||
|
| Mouse | Whole brain | PN 70 | 10% v/v | Free drinking | GD 1 - PN 10 | 27 | 0% | ||||||||
|
| Mouse | Hippocampus | PN 70 | 2.5 g/kg (2× at 0 h and 2 h) | Subcut. injection | PN 4,7 | 38 | 7.9% | IL18, VDR | IL18, TAC1 | VDR | |||||
|
| Rat | DRG-derived neural stem cells (cultured) | NA | 400 mg/dL | 6 h | NA | 91 | 12.1% | AQP9, CRABP1, OASL1, TNF | ARMET, CLCF1, INSL6, TNF | PIK3R1, PTPRC, TNF | NCR3, PIK3R1, SH3BP2, TNF | ||||
|
| Rat | Hypothalamus | PN 1, 7, 14, 21 | Liquid ethanol diet | 22 days | GD1-22 | 34 | 11.8% | CCRL2, IL20RA | |||||||
|
| Rat | Hypothalamus; white blood cells | PN21 | Liquid ethanol diet | 22 days | GD1-22 | 32 | 9.4% | AP3B1 | FGF9 | IL18R1 | |||||
|
| Human | Embryonic stem cells (cultured) | NA | 20 mM | 4 days | NA | 0 | NA | ||||||||
|
| Human | Embryonic stem cells (cultured) | NA | 20 mM or 50 mM | 1 or 2 days | NA | 392 | 12.2% | MR1 | CABP1, CCBP2, CCL11, CXCL2, | CD96, | CCL11, CMTM6, | CCBP2, CSF3R, ESR1, | CARD11, IL2, IL4, SYK, ZAP70 | ||
|
| Human | Buccal epithelial cells | 3–6 years | Confirmed FASD | 199 | 5.0% | COLEC11 | CMTM2, PDGFRL, | ESRRG, FGFR3, | IFITM1, LYN | ||||||
|
| Human | Buccal epithelial cells | 5–18 years | Confirmed PAE | 465 | 7.1% |
| BCL3, CCR3, | C1R, C1S, CD47, CSMD1 | CSF2, FGF21, GDF15, LHB, PROK1, UCN3 | BMPR1B, CALCR, CCR3, CRHR2, ESRRB, LAP3, PTH1R, ROBO3, RXRA, | CSF2, NFATC1 | CSF2, | |||
|
| Human | Buccal epithelial cells | 3.5–18 years | Confirmed FASD | 143 | 6.3% | HLA-DPA1, | AGT, FGF12 | AKT3 | KLRK1 | ||||||
|
| Human | Cord blood | Birth | Sustained drinking through pregnancy | 86 | 5.8% | NFYA, TAPBP | NR2E1 | ||||||||
| Binge | 158 | 8.9% | CACYBP, CXCL12, GDA, IL29, NFKBIZ, RPF1 | CFHR2 | ANGPTL5, CXCL12, IL29, LTBP4, PYY, TNFRSF11B | NR2F2, ROBO2, TNFRSF1A | ||||||||||
| First trimester exposure | 35 | 11.4% |
| FGF6, | CXCR7, RORB | |||||||||||
| Second and third trimester exposure | 81 | 4.9% | HLA-C | ATF1, | IKBKB | HLA-C | ||||||||||
|
| Human | Buccal epithelial cells | 7.44 years ± 0.55 | >30 ng/g ethyl glucuronide (EtG) in meconium at birth | 189 | 7.4% | HSPA4 | AHNAK, DEFB121, PENK, SRC | ITGB2 | MTNR1B, NRP1, SCTR | PIK3CD | ITGB2, PIK3CD | ||||
|
| Human | Blood | 1.0–18.4 years | Confirmed FASD | 18 | 5.6% | TNFRSF19 | |||||||||
|
|
| Mouse | Hippocampus | PN 70 | 2.5 g/kg (2× at 0 h and 2 h) | Subcut. injection | PN 4, 7 | 35 | No immune genes identified in top 40 differential loci | |||||||
|
|
| Mouse | Hippocampus | PN 70 | 2.5 g/kg (2× at 0h and 2h) | Subcut. injection | PN 4, 7 | 39 | 2.6% | S1pr2 | ||||||
*Data were obtained from
The cytokines and chemokines category includes chemokines, cytokines, interleukins, TGFb family members, TNF family members, and interferons (none found).
The receptors category includes receptors for chemokines, cytokines, interleukins, TGFb family members, TNF family members, and interferons (none found).
The B or T cell signaling category includes BCR signaling pathways and TCR signaling pathway.